Results 1 to 10 of about 9,189 (185)

Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. [PDF]

Antimicrob Agents Chemother
ABSTRACT Aztreonam-avibactam, a fixed-ratio (3:1) β-lactam/β-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired/ventilator-associated ...
Xie R, Rogers H, Chow JW, Soto E, Raber SR.   +4 more
europepmc   +4 more sources

Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens. [PDF]

Pharmacotherapy
AbstractAntimicrobial resistance poses a significant public health challenge, particularly with the rise of gram‐negative hospital‐acquired infections resistant to carbapenems. Aztreonam–avibactam (ATM–AVI) is a promising new combination therapy designed to combat multidrug‐resistant (MDR) gram‐negative bacteria, including those producing metallo‐β ...
Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ.   +5 more
europepmc   +3 more sources

Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales. [PDF]

Antimicrob Agents Chemother
Castanheira M, Kimbrough JH, Morgan GM, Karr M, Sader HS.   +4 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Aztreonam-Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain. [PDF]

Infect Dis Ther
Aguilar G, Ruiz-Garbajosa P, Periañez Parraga L, Maroto-Díaz M, de Ceano-Vivas MDC, Villacampa Lordan A, Arranz Gonzalo S, de Lossada Juste A, Moya-Alarcón C, Gheorghe M, Torre-Cisneros J.   +10 more
europepmc   +1 more source

Antimicrobial susceptibility of Enterobacterales causing infection in the elderly: focus on aztreonam-avibactam and recently approved β-lactamase inhibitor combinations. [PDF]

JAC Antimicrob Resist
Sader HS, Mendes RE, Kimbrough JH, Papp-Wallace KM, Winkler ML, Castanheira M.   +5 more
europepmc   +1 more source

Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing <i>Enterobacter cloacae</i>. [PDF]

Antibiotics (Basel)
Keck JM, Dare RK, Saccente M, Vyas KS, Thompson RN.   +4 more
europepmc   +1 more source

<i>In vitro</i> activity of aztreonam-avibactam and distribution of carbapenemase genes in ceftazidime-avibactam-resistant carbapenem-resistant Enterobacterales: data from the global Antimicrobial Testing Leadership and Surveillance, 2019-2023. [PDF]

Antimicrob Agents Chemother
Lee Y-L, Wang W-Y, Huang Y-T, Ho M-W, Ko W-C, Hsueh P-R.   +5 more
europepmc   +1 more source

Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). [PDF]

JAC Antimicrob Resist
Daikos GL, Cisneros JM, Carmeli Y, Wang M, Leong CL, Pontikis K, Anderzhanova A, Florescu S, Kozlov R, Rodriguez-Noriega E, Psichogiou M, Rattanaumpawan P, Streinu-Cercel A, Ramasubramanian V, Arhin FF, Rogers H, Wible M, Leaney J, Jacobson D, Pypstra R, Chow JW.   +20 more
europepmc   +1 more source

Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested Against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019-2023). [PDF]

Antibiotics (Basel)
Sader HS, Winkler ML, Papp-Wallace KM, Mendes RE, Castanheira M.   +4 more
europepmc   +1 more source